On April 1, 2024, Aditxt, Inc. entered into an agreement for Adivir, its subsidiary, to acquire Appili Therapeutics, with multiple amendments extending deadlines for completion and financial disclosures through early 2025, including a $250,000 fee paid to Appili on various dates.